[go: up one dir, main page]

DE60117594D1 - 3-oxadiazol-5-yl-1-aminoalkyl-1h-indolderivate - Google Patents

3-oxadiazol-5-yl-1-aminoalkyl-1h-indolderivate

Info

Publication number
DE60117594D1
DE60117594D1 DE60117594T DE60117594T DE60117594D1 DE 60117594 D1 DE60117594 D1 DE 60117594D1 DE 60117594 T DE60117594 T DE 60117594T DE 60117594 T DE60117594 T DE 60117594T DE 60117594 D1 DE60117594 D1 DE 60117594D1
Authority
DE
Germany
Prior art keywords
oxadiazol
aminoalkyl
sub
indole derivatives
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60117594T
Other languages
English (en)
Inventor
Gerard Moloney
Duncan Robertson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL IP Investments Pty Ltd
Original Assignee
Amrad Operations Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amrad Operations Pty Ltd filed Critical Amrad Operations Pty Ltd
Application granted granted Critical
Publication of DE60117594D1 publication Critical patent/DE60117594D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60117594T 2000-11-02 2001-11-02 3-oxadiazol-5-yl-1-aminoalkyl-1h-indolderivate Expired - Lifetime DE60117594D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR1180A AUPR118000A0 (en) 2000-11-02 2000-11-02 Therapeutic molecules and methods
PCT/AU2001/001417 WO2002036590A1 (en) 2000-11-02 2001-11-02 3-oxadiazol-5-yl-1-aminoalkyl-1h-indole derivatives

Publications (1)

Publication Number Publication Date
DE60117594D1 true DE60117594D1 (de) 2006-04-27

Family

ID=3825223

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60117594T Expired - Lifetime DE60117594D1 (de) 2000-11-02 2001-11-02 3-oxadiazol-5-yl-1-aminoalkyl-1h-indolderivate

Country Status (8)

Country Link
US (1) US6930118B2 (de)
EP (1) EP1339710B1 (de)
JP (1) JP2004517822A (de)
AT (1) ATE318810T1 (de)
AU (2) AUPR118000A0 (de)
CA (1) CA2427394A1 (de)
DE (1) DE60117594D1 (de)
WO (1) WO2002036590A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200407110A (en) 2001-11-23 2004-05-16 Astrazeneca Ab New use for the treatment of gastroesophageal reflux disease
JP2005533748A (ja) 2002-03-08 2005-11-10 シグナル ファーマシューティカルズ,インコーポレイテッド 増殖性障害および癌を治療、予防、または管理するための併用療法
BR0313041A (pt) * 2002-07-29 2005-06-21 Hoffmann La Roche Compostos; composições farmacêuticas; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação dos receptores de cb1; e uso de compostos
SE0203070D0 (en) 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds
DK1637527T3 (da) * 2003-06-26 2013-07-01 Takeda Pharmaceutical Cannabinoid receptor modulator.
US20070135485A1 (en) * 2003-10-22 2007-06-14 Gillig James R Novel mch receptor antagonists
TWI330635B (en) 2004-03-05 2010-09-21 Organon Nv (indol-3-yl)-heterocycle derivatives
BRPI0514572A (pt) 2004-08-23 2008-06-17 Wyeth Corp ácidos de tiazolo-naftila
KR20070055563A (ko) 2004-08-23 2007-05-30 와이어쓰 혈전증 및 심혈관 질병의 치료에 유용한 플라스미노겐활성화제 억제제 타입-1(pai-1)의 조절제로서의옥사졸로-나프틸 산
US7186749B2 (en) 2004-08-23 2007-03-06 Wyeth Pyrrolo-naphthyl acids and methods for using them
JPWO2006080284A1 (ja) * 2005-01-25 2008-06-19 塩野義製薬株式会社 2−置換イミノ−1,3−オキサジン誘導体
TW200745096A (en) * 2005-08-23 2007-12-16 Organon Nv Indole derivatives
US7763732B2 (en) 2005-08-24 2010-07-27 N.V. Organon Indole derivatives
GB0614062D0 (en) * 2006-07-14 2006-08-23 Glaxo Group Ltd Compounds
TW200848417A (en) * 2007-02-22 2008-12-16 Organon Nv Indole derivatives
RU2404185C1 (ru) * 2009-04-16 2010-11-20 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) РАВНОМЕРНО МЕЧЕННЫЙ ТРИТИЕМ (R)-(+)-[5-МЕТИЛ-3-(4-МОРФОЛИНИЛМЕТИЛ)-2,3-ДИГИДРО-[1,4]ОКСАЗИНО [2,3,4-hi]-6-ИНДОЛИЛ]-1-НАФТАЛИНИЛМЕТАНОН АЦЕТАТ
CN110627778B (zh) * 2018-06-25 2023-01-24 中国科学院上海药物研究所 一类含有1,2,4-噁二唑环的化合物、其制备方法及其在免疫抑制药物中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ227841A (en) * 1988-02-12 1991-08-27 Merck Sharp & Dohme Heterocyclic compounds with at least two non-condensed five membered rings and pharmaceutical compositions
US4939138A (en) * 1988-12-29 1990-07-03 Sterling Drug Inc. 2- and 3-aminomethyl-6-arylcarbonyl-2,3-dihydropyrrolo(1,2,3-DE)-1,4-benzoxazines
US5068234A (en) * 1990-02-26 1991-11-26 Sterling Drug Inc. 3-arylcarbonyl-1-(c-attached-n-heteryl)-1h-indoles
US4973587A (en) * 1990-03-08 1990-11-27 Sterling Drug Inc. 3-arylcarbonyl-1-aminoalkyl-1H-indole-containing antiglaucoma method
US5013837A (en) * 1990-03-08 1991-05-07 Sterling Drug Inc. 3-Arylcarbonyl-1H-indole-containing compounds
EP0596933A1 (de) * 1991-08-03 1994-05-18 Smithkline Beecham Plc 5-HT4 Rezeptor - Antigonisten
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5532237A (en) 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
EP1339710A1 (de) 2003-09-03
AUPR118000A0 (en) 2000-11-23
US20040034073A1 (en) 2004-02-19
CA2427394A1 (en) 2002-05-10
EP1339710A4 (de) 2004-05-12
AU1366802A (en) 2002-05-15
JP2004517822A (ja) 2004-06-17
EP1339710B1 (de) 2006-03-01
US6930118B2 (en) 2005-08-16
WO2002036590A1 (en) 2002-05-10
ATE318810T1 (de) 2006-03-15

Similar Documents

Publication Publication Date Title
ATE318810T1 (de) 3-oxadiazol-5-yl-1-aminoalkyl-1h-indolderivate
DE60012188D1 (de) Fungizide
MXPA03004549A (es) Derivados de 3-arilindola y su uso como agonistas del receptor cb2.
ATE383856T1 (de) (4-hydroxyphenyl)-1h-indol-3-carbaldehydoxim- derivative als östrogenagentien
ATE269312T1 (de) N-(amidinophenyl)-n'-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
DE60230127D1 (de) Inhibitoren von integrin alpha-v-beta-6
BR0313420A (pt) Quinolonas microbicidas, suas composições e usos
ES2243579T3 (es) Derivados de pirazolopirideno.
SE0004245D0 (sv) Novel compounds and their use
MXPA03002911A (es) Compuestos quimicos.
MXPA02012076A (es) Compuestos quimicos.
AU2001266575A1 (en) Chemical compounds
TR200201683T2 (tr) İkameli fenil-piperazin türevleri, bunların hazırlanması ve kullanımları
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
DE60112960D1 (de) Kondensierte pyridoindolderivate
TR200101979T2 (tr) Antidepresyon tedavisi için 5HT1 antagonistleri.
ATE433458T1 (de) Modulatoren von ship-1
PT1089625E (pt) Agentes ectoparasiticidas
TR200001909T2 (tr) Matris metaloprotez inhibitörleri.
DE60121048D1 (de) PYRAZINOi1'2':1,6öPYRIDOi3,4-BöINDOLDERIVATE
DK1204659T3 (da) Serotonerge benzofuraner
ATE280169T1 (de) Serotonerge benzothiophene
TR200401052T4 (tr) Yeni bileşikler
AU2002211493A1 (en) Indole derivatives as pde5-inhibitors
SE9904128D0 (sv) Novel compounds

Legal Events

Date Code Title Description
8332 No legal effect for de